Zhitong Finance App News, Tongyuankang Pharmaceutical-B (02410.HK) announced that the new-generation EGFR-TKI innovative drug deuterosenitinib mesylate tablets (TY-9591 tablets) independently developed by the company has been approved by the China National Drug Administration (NMPA) for conditional marketing. The indications are partial or advanced metastases of exon 21 (L858R) with epidermal growth factor receptor (EGFR) exon 19 deficiency (19DEL) or exon 21 () replacement mutations, accompanied by central nervous system (CNS) metastases non-small cell lung cancer (NSCLC) First-line treatment for adult patients.
Zhitongcaijing · 1d ago
Share
Listen to the news
Zhitong Finance App News, Tongyuankang Pharmaceutical-B (02410.HK) announced that the new-generation EGFR-TKI innovative drug deuterosenitinib mesylate tablets (TY-9591 tablets) independently developed by the company has been approved by the China National Drug Administration (NMPA) for conditional marketing. The indications are partial or advanced metastases of exon 21 (L858R) with epidermal growth factor receptor (EGFR) exon 19 deficiency (19DEL) or exon 21 () replacement mutations, accompanied by central nervous system (CNS) metastases non-small cell lung cancer (NSCLC) First-line treatment for adult patients.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending